Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients

Leukemia

Volumn 13, Issue 2, 1999, Pages 166-174

  Osman, Y ^a   Takahashi, M ^b   Zheng, Z ^a   Koike, T ^a   Toba, K ^a   Liu, A ^a   Furukawa, T ^a   Aoki, S ^a   Aizawa, Y ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Bcr abl peptide; CML; Cytotoxic T lymphocytes; Dendritic cells; DLT

Indexed keywords

BCR ABL PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE MARROW CELL; CELL MEDIATED CYTOTOXICITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA MATCHING; HUMAN; HUMAN CELL; LEUKOCYTE TRANSFUSION; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0033063104     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401311     Document Type: Article

References (37)

1. Kolb H, Schattenburg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Neiderwieser D, van Rhee F, Mittermueller J, de Titte T, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
2. Hill GR, Hart DNJ, Moore AF, Morris CM. Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse post bone marrow transplantation. Pathology 1996; 28: 51-53.
3. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
4. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-58.
5. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995; 1: 1297-1302.
6. Grabbe S, Beissert S, Schwartz T, Granstein RD. Dendritic cells as initiators of tumor immune response: a possible strategy for immunotherapy? Immunol Today 1995; 16: 117-121.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
8. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
9. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
10. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
11. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319: 990-998.
12. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase 1 clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. The Prostate 1996; 29: 371-380.
13. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998; 4: 957-962.
14. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-332.
15. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-1142.
16. + T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997; 90: 290-297.
17. 1+) human leukemia lines can also recognize Ph1-cells from the same patient. Blood 1994; 83: 3390-3402.
18. BCR-ABL protein by human T cells. Leukemia 1995; 9: 1344-1348.
19. + T cells elicited by primary in vitro immunization with a bcr-abl breakpoint peptide. Blood 1996; 88: 3522-3527.
20. Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, Kalbacher H. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996; 88: 2118-2124.
21. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998; 91: 977-983.
22. Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti E, Butler R, Tanigaki N, Tosi R. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10: 693-699.
23. O'Doherty U, Steinman RM, Peng M, Cameron PU, Gezelter S, Kopeloff I, Swiggard WJ, Pope M, Bhardwaj N. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med 1993; 178: 1067-1076.
24. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, Steinman RM. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82: 487-493.
25. + blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection. J Immunol 1994; 152: 4649-4662.
26. Toba K, Koike T, Takahashi M, Kishi K, Hashimoto S, Takahashi H, Uesugi Y, Ishikawa T, Aoki S, Maeo S, Naito M, Aizawa Y, Shibata A. Characterization and sensitivity to interleukin-2 and interferon-α of leukemic cells from a patient with large granular lymphocytic leukemia associated with chronic active Epstein-Barr virus infection. Leukemia Res 1997; 21: 941-950.
27. Gausepohl H, Boulin C, Kraft M, Boulin C, Frank RW. Automated multiple peptide synthesis. Pept Res 1992; 5: 315-320.
28. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.
29. Tsai V, Kawashima I, Keogh E, Daly K, Alessandro S, Celis E. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 1998; 18: 65-75.
30. Ostankovitch M, Buzyn A, Bonhomme D, Connan F, Bouscary D, Heshmati F, Dreyfus F, Choppin J, Guillet JG. Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts. Blood 1998; 92: 19-24.
31. Uchida A, Micksche M. Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions. Int J Cancer 1983; 32: 37-44.
32. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990; 172: 631-640.
33. Epstein MM, Di Rosa F, Jankovic D, Sher A, Matzinger P. Successful T cell priming in B cell-deficient mice. J Exp Med 1995; 182: 915-922.
34. + T lymphocytes to peptide antigen in vivo. J Immunol 1993; 151: 6742-6750.
35. Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993; 329: 1-9.
36. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995; 16: 2-4.
37. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A. Specific binding of leukaemia oncogene fusion protein peptides to HLA class 1 molecules. Blood 1995; 85: 2680-2684.